FDA Approves Ubrogepant for Acute Treatment of Migraine What the Data Show – Neurology Today

Read article - Quotes Stewart Tepper, professor of neurology, in an article about how a new oral agent, ubrogepant, was approved by the U.S. Food and Drug Administration for treatment of acute migraine. "The advantage of this drug and of its cousin (rimegepant) is the side effects are really minimal," said Tepper.